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Relationship between PON1 phenotype and headache
duration in migraine patients
Şahbettin SELEK1, Recep ALP2, Selen İLHAN ALP2, Abdullah TAŞKIN3

Aim: The available data on the activity of paraoxonase-1 (PON1) in patients suffering from migraine without aura
(MWoA) is scarce. The present study was conducted to fulfill the objective of investigating the probability of an
association between PON1 phenotype distribution and headache duration in patients suffering from MWoA.
Materials and methods: Seventy-six patients who suffer from MWoA and were not experiencing attacks at the time and
65 healthy volunteers were enrolled for the purpose of evaluation in the present study.
Results: The levels of serum paraoxonase, arylesterase activities, and lipid hydroperoxide (LOOH) were determined
for these subjects. The results obtained revealed that no statistical differences existed between the group suffering from
MWoA and the control group with respect to the PON1 activity and the phenotype distribution (all values of P > 0.05),
while the levels of serum LOOH were noted to be higher (P < 0.05) in the patient group. However, a significant relation
was found between the PON1192QR phenotype distribution and headache duration in patients suffering from MWoA
(P < 0.001). It was observed that patients with the PON1192RR (BB = homozygous high activity) polymorphism had
headaches of shorter duration than patients with the PON1192QQ (AA = homozygous low activity) and PON1192QR
(AB = heterozygous intermediate activity) polymorphisms. Along with these results, significant negative correlations
were found between the ratio of salt-stimulated paraoxonase/arylesterase and headache duration (r: -0.40, P < 0.001)
in patients suffering from MWoA in comparison to the control group. Finally, the activities of both paraoxonase and
arylesterase were found to be inversely correlated with the levels of serum LOOH in the patient group [(r: -0.23, P <
0.05) and (r: -0.27, P < 0.05), respectively].
Conclusion: The results ascertained through the present study suggest that a significant correlation exists between
PON1 phenotype distribution and headache duration in patients suffering from MWoA. Additionally, to the best of
our knowledge, this is the first study to evaluate the association between PON1 polymorphism and headache duration
in patients with migraine. PON1 phenotype distribution will play a key role in headache duration in patients with
migraine.
Key words: Paraoxonase, arylesterase, phenotype, lipid hydroperoxide

Migrenli hastalarda PON1 fenotip ile başağrısı süresi arasındaki ilişki
Amaç: Aurasız Migrenli hastalar ile paraoksanaz-1 aktivitesi arasındaki bilgiler yok denecek kadar azdır. Bizler bu
çalışmamızda aurasız migrenli hastalarda PON1 fenotipik dağılım ile baş ağrısı süresi arasındaki ilişkiyi ortaya koymaya
çalıştık.
Yöntem ve gereç: Bu çalışmaya 76 tane aurasız migrenli hasta ile hayatlarının herhangi bir döneminde hiç migren atağı
geçirmemiş 65 gönüllü sağlıklı hasta dahil edildi.
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Bulgular: Her iki gruptada serum paraoksonaz/arilesteraz aktivitesi ve lipid hidroperoksitleri ölçüldü. Elde edilen
sonuçlar değerlendirildiğinde hasta grubunda lipid hidroperoksitlerinde belirgin bir artış gözlenirken (P < 0,05), PON1
fenotip dağılımı ve paraoksanaz/arilesteraz aktiviteleri her iki gurup arasında istatistiksel olarak herhangi bir fark yoktu
(P > 0,05), Ancak, hasta grubunda PON1 fenotip dağılımı ile başağrısı süresi arasında anlamlı bir ilişki tespit edildi (P
< 0,001). Böylece, PON1192RR (BB = homozigot yüksek aktivite) polimorfizimine sahip olan hastalarda başağrısı süresi
PON1192QQ (AA = homozigot düşük aktivite) ve PON1192QR (AB = heterozigot orta düzey aktivite) polimorfizimine
sahip hastalarda daha kısa süreli olarak gözlemlendi. Bu sonuçlarla ilişkili olarak salt stimulated paraoksanaz/arilesteraz
oranı ile aurasız migrenli hastalardaki başağrısı süresi ile anlamlı derecede bir koreleasyon tespit edildi (r : -0,40; P <
0,001). Ayrıca hasta grubunda hem paraoksanaz hem de arilesteraz aktiviteleri, lipid hidroperoksitleri ile ters bir şekilde
korele idi (sırasıyla, [(r : -0,23; P < 0,05); (r : -0,27; P < 0,05)].
Sonuç: Bu çalışmada elde edilen sonuçlar değerlendirildiğinde; aurasız migrenli hastalarda başağrısı süresi ile PON1
fenotipik dağılım arasında anlamlı bir korelasyon tespit edildi. Buna ilaveten, Bizim bilgilerimize göre böyle bir
çalışma ilk kez bizim tarafımızdan yapılmış olup, PON1 fenotipik dağılımın migren başağrısı süresinde önemli bir rol
alabileceğini ortaya koymaktadır.
Anahtar sözcükler: Paraoksanaz, arilesteraz, fenotip, lipid hidroperoksit

Introduction
Migraine is a complex disorder that incorporates
certain neuronal and vascular disturbances within
itself. The exact mechanism that represents the
pivotal step in the etiology of the headache and
the reason women are 3 times more susceptible to
migraine than men are still unknown (1). Several
studies indicate that migraine is associated with the
presence of adverse vascular risk factors including: an
increased level of oxidative stress and thrombosis (2),
an increase in body weight (3), high blood pressure
(4), hyperlipidemia (5), impaired insulin sensitivity
(6), high homocysteine levels, strokes, and coronary
artery diseases (CAD) (7-9).
Serum paraoxonase-1 (PON1) is a glycoprotein
synthesized mainly by the liver that circulates in
serum in association with high-density lipoprotein
(HDL) (10); moreover, it is a Ca2+-dependent serum
esterase that is widely distributed in liver, kidney, and
intestine tissues, as well as serum (11). It is a protein
comprising 354 amino acids with a molecular mass
of 43 kDa, and plays a key role in the protection
of low-density lipoprotein (LDL) and HDL from
the oxidation process by hydrolyzing the activated
phospholipids and lipid peroxide products (12).
Previous studies have demonstrated that the activity
of serum PON1 is associated with the modulation of
endothelial functions (13), the regulation of coronary
vasomotor tone, and the occurrence and extent of
CAD (14).
Epidemiological studies have revealed wide
variation among individuals in serum PON1 activity.
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It is known that PON1 has at least 5 polymorphic
forms. Among these, 2 major polymorphic structures
form at codon 192 [A/G: Gln (Q)/Arg (R)] and
codon 55 [T/A: Leu(L)/Met (M)], and these were
demonstrated to correlate with enzyme activity
(15,16). The position of the 192 Q/R polymorphisms
is the major determinant of the resultant PON1activity polymorphisms. The occurrence and types
of polymorphisms affect the hydrolytic activity of the
PON1 isoenzymes with respect to certain substrates
such as paraoxon and lipid peroxides (16,17). Further,
it has been suggested that a low rate of PON1 activity
is induced by CAD. In addition, this activity, usually
measured by using paraoxon as a substrate, is under
genetic and environmental regulation and appears
to vary widely among individuals and between
populations (15,16,18).
Many researchers have suggested that the
occurrence of migraine is biologically linked to
the occurrence of CAD (19). It is also thought
that hyperlipidemia plays a significant role in the
pathogenesis of migraine (5,7,8). Additionally, the
presence of hyperlipidemia and a decreased rate of
PON1 activity were suggested as risk factors for stroke
and CAD (17). Data is not yet available, however,
regarding the role it plays in inducing migraine. The
purpose of the present study was to examine the role
that phenotype distribution and PON1 activity play
in influencing the duration of migraine incidents. To
the best of the authors’ knowledge there has only been
one similar study, and it demonstrated that PON1
genotype polymorphisms and allelic variants were
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not related to risk for migraine in Caucasian Spanish
people (20). The results of this study supported the
results of our study, which examined phenotype
distribution of PON1 in patients suffering from
migraine without aura (MWoA). However, there are
no available reports investigating the relationship
between phenotype distribution of PON1 and
headache duration in patients suffering from MWoA.
Materials and methods
Subjects
The present study was conducted at the Neurology
Outpatient Clinic of Kafkas University, located in
Kars in northeastern Turkey. The evaluated group
consisted of 76 patients diagnosed with MWoA
during a headache-free period. The mean age of
the 55 female and 21 male patients included in the
study was 31 ± 10 years. Their diagnosis was based
on clinical symptoms in accordance with those
symptoms established by the International Headache
Society (IHS) in 2004 (21). The IHS conducted
experiments to evaluate the parameters of headache
duration, frequency, localization, severity, and the
entire duration of the migraine incident. In order
to assess the severity of headache the Migraine
Disability Assessment (MIDAS) and Visual Analog
(VAS) scale were employed (21,22). The factors of
pregnancy, lactation, clinically unstable medical
illness, or the use of any medication 3 weeks prior
to initiation of the study were excluded. Sixty-five
healthy volunteers (with mean age 31 ± 9 years;
including 41 women and 24 men) were enrolled to
constitute the control group in the present study. A
thorough history of headache was acquired for all the
subjects evaluated in the control group, and none of
them were found to suffer from a headache disorder.
Further, none of the subjects included in the present
study revealed a history of any medical illness, nor
had they taken any analgesics, ergot alkaloids, or any
other drugs at least 3 weeks prior to inclusion in the
study. None of the evaluated patients were under
prophylactic treatment for their migraine disorder.
For both patient and control groups hematological
and biochemical parameters were determined on a
regular basis. Moreover, both these groups consisted
of non-smokers. The characteristics of the evaluated
patients are given in Table 1.

The protocol followed in the present study was in
accordance with the Helsinki Declaration, revised in
1989. For conducting the evaluations in the present
study, the approval of the ethics committees of the
Medical Faculty of the Kafkas University and the
informed consent of the patients and the healthy
individuals were sought and attained.
Exclusion criteria
The exclusion criteria for conducting evaluations in
the present study included the usage of supplemental
vitamins, respiratory disorders, HIV positive
status, the habit of smoking, a diagnosis of diabetes
mellitus or CAD, rheumatoid arthritis, malignancy,
hypertension, acute-chronic liver diseases, renal
dysfunction, and headaches. In addition, the presence
of any disease related to headache occurrence was
considered part of the exclusion criteria (this includes
diseases of intracranial neoplasm, sarcoidosis and
inflammatory diseases, facial or cranial structure
disorders, cranial neuralgias, nerve trunk pain,
and temporal arthritis). In order to conduct the
evaluations, blood samples were obtained from the
subjects following an overnight fast. The samples
were collected in empty test tubes and immediately
stored on ice at 4 °C. The serum samples were then
separated from the cells by centrifugation at 3000
rpm for 10 min. The resultant serum samples were
stored at −81 °C until their use in the experimental
analysis.
Measurement of the rate of paraoxonase and
arylesterase activities
Paraoxonase and arylesterase activities were
measured with the commercially available Rel
Assay Diagnostics kits (23) that are equipped with
an auto analyzer (Aeroset®, Abbott®, Illinois, USA).
Measurements to determine the rate of paraoxonase
activity were performed in the alternating absence
(basal activity) and presence of sodium chloride
(NaCl) (salt-stimulated activity) by using the paraoxon
substrate. The rate of the paraoxon hydrolysis
(diethyl-p-nitrophenyl phosphate) was measured by
monitoring the increase in the rate of absorbance at
412 nm. The amount of generated p-nitrophenyl was
calculated from the molar absorptivity coefficient at
a pH value of 8, which was 17.000 M−1 cm−1. The rate
of activity was measured briefly at 37 °C by adding
20 μL of the stored serum to 200 μL of the Tris buffer
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(0.1 M, pH: 8.0), which contained 2 mM of CaCl2 and
7 mM of paraoxon. The rate of paraoxonase activity
was expressed as the unit U/L serum (11,13,16,23).
Next, in order to measure the rate of the arylesterase
activity, phenylacetate was employed as a substrate.
The required reaction was initiated by adding the
stored serum to the substrate and then reading the
increase in the degree of absorbance at 270 nm. The
blank readings were included in the evaluations
to correct the value obtained for the spontaneous
process of phenylacetate hydrolysis. The rate of
enzymatic activity was calculated from the molar
absorptivity coefficient of the produced phenol, 1310
M−1 cm−1. For the evaluations conducted here one
unit of the degree of arylesterase activity was defined
as 1 μmol of phenol generated/min under the above
conditions and expressed by the unit U/L serum. The
phenotype distribution of PON1 was determined
in the presence of 1 mol/L of NaCl (salt-stimulated
paraoxonase). The ratio of the salt-stimulated
paraoxonase activity to the degree of arylesterase
activity was used to allocate the subjects to one of
3 possible phenotypes (11,13,16,23). The subjects
were assigned to 1 of the following 3 phenotypes:
QQ (homozygous low activity), QR (heterozygous
activity), or RR (homozygous high activity). These
phenotypes are defined by the ratio of the degree
of activity with the ranges 0.73 ± 0.23 for QQ (AA),
2.9 ± 0.49 for QR (AB), and 5.09 ± 0.18 for RR (BB)
(Figure 2).
Measurement of the level of serum LOOH
The serum LOOH levels were measured with
a ferrous ion oxidation–xylenol orange assay. This
particular assay depends on the oxidation of ferrous
ion to ferric ion through the effect of various oxidants.
Consequently, the ferric ion produced is measured
with xylenol orange. The level of LOOH is reduced by
the application of triphenyl phosphine (TPP), which
is a specific reductant for lipids. The LOOH levels can
be estimated through the difference in values that
appear due to the absence or presence of TPP (24).
Other parameters
The levels of HDL-C, LDL-C, total cholesterol
(TC), and triglyceride (TG) were measured through
the commercially available assay kits (Abbott®,
Illinois, USA) that are equipped with an autoanalyzer
(Aeroset®, Abbott®, Illinois, USA).
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Statistical analysis
The collected data was expressed as the mean
± standard deviation (X ± SD). The student T test
was employed to compare the parameters of both
these groups. The chi-square test was used to test
the distribution of the phenotype. In addition, the
correlations existing between the parameters in
both groups were determined through Pearson’s
correlation analysis. A linear regression analysis was
used to determine the exact relationships that existed
between the parameters of age and gender among
the evaluated subjects; migraine duration; headache
frequency; the mean value of VAS; the mean value
of MIDAS; the serum TG, TC, HDL-C, and LDL-C
levels; and the degree of PON1 activities, or the LOOH
levels. P-values < 0.05 were accepted as significant.
The data was analyzed by using a computer program.
Results
The demographic, clinical, and laboratory data
of both groups are given in Table 1 and Table 2. No
statistically significant differences were recorded
between the groups with respect to the parameters
of age and gender (both at a value of P > 0.05). The
polymorphism data and the allele frequencies of
the study groups are given in Table 3. Finally, the
phenotype distribution of the patients is illustrated
in Figure 1. No significant differences were found
to exist between the patients suffering from MWoA
and the control group (P > 0.05) on the basis of the
rate of activity of serum PON1 and the phenotype
distribution; a significant difference appeared in the
levels of serum LOOH between the patients and the
controls (P < 0.05). The activities of both paraoxonase
and arylesterase were found to be inversely correlated
with the levels of serum LOOH in patients diagnosed
with MWoA (r: -0.23, P < 005; r: -0.27, P < 0.05,
respectively). In addition, significant differences were
noted between the PON1 phenotype distribution
and headache duration in patients diagnosed with
MWoA, as determined through the chi-square test (P
< 0.001), in comparison to the control group. The ratio
of salt-stimulated paraoxonase activity to arylesterase
activity correlated with headache duration (r = -0.40,
P < 0.001) (Figure 3). The concentrations of serum
TC, TG, and LDL-C were found to be significantly
higher in the patients diagnosed with MWoA in

Ş. SELEK, R. ALP, S. İLHAN ALP, A. TAŞKIN

Table 1. The demographic and clinical features of patients diagnosed with MWoA and control group.*
MWoA patients

Controls

Value of P

Age (years)

31 ± 10

31 ± 9

> 0.5

Sex (F/M)

55/ 21

41/ 24

Mean body mass index

26.4 ± 3.3

24.8 ± 3.9

Migraine duration (years)

6.2 ± 4.2

Headache frequency (per month)

7.3 ± 5.2

Headache duration (h)

> 0.5

30.41 ± 19.56

Mean value of VAS

8.8 ± 1.1

Mean value of MIDAS

12.6 ± 6.4

*The data are presented as mean ± SD

Table 2. Comparison of PON1 activity and laboratory parameters in patients diagnosed with MWoA and the control group.*
Parameters

MWoA patients

Controls

Value of P

Paraoxonase (U/L)

166 ± 90

171 ± 83

Ns

Salt-stimulated paraoxonase (U/L)

391 ± 257

400 ± 290

Ns

Arylesterase (kU/L)

174 ± 32

177 ± 36

Ns

LOOH (μmol/L)

8.5 ± 2.0

7.1 ± 2.3

< 0.05

TG (mg/dL)

145 ± 80

129 ± 60

< 0.05

TC (mg/dL)

213 ± 24

194 ± 26

< 0.05

HDL-C (mg/dL)

37 ± 6.3

34 ± 4.2

Ns

LDL-C (mg/dL)

147 ± 4.6

134 ± 9.7

< 0.05

*The data are presented as mean ± SD; Ns: non-significant

Table 3. Phenotype distribution in patients diagnosed with MWoA and the control group.*
Phenotype distribution

Migraine patients n (%)

Controls n (%)

Value of P

BB

8 (11)

6 (9)

> 0.05

AB

28 (37)

27 (42)

> 0.05

AA

40 (53)

32 (49)

> 0.05

Total

76

65

*The data are presented as n (%)
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Figure 1. PON1 phenotype distribution in patients with MWoA.
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It was also noted that PON1 activity and serum
LOOH levels were not correlated with the age and
gender of the subjects; migraine duration; headache
frequency; the mean value of VAS; mean value of
MIDAS; or the levels of serum TG, TC, HDL-C, or
LDL-C (P > 0.05).
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5
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Figure 2. The ratio of salt-stimulated paraoxonase/arylesterase
in MWoA patients.

comparison to the controls (for all parameters the
value of P < 0.05); no differences were noted in the
levels of HDL-C between the 2 groups (P > 0.05).
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Figure 3. The ratio of salt-stimulated paraoxonase to arylesterase
and headache duration.
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Headache duration (hour)

The role of hyperlipidemia in influencing incidents
of migraine is uncertain, since only a few studies have
been conducted to evaluate the correlation between
incidents of migraine and hyperlipidemia (5). The
present study aimed to evaluate the association that
exists between cardiovascular biomarker (PON1)
activity and incidents of migraine. Further, this
patient-control study was performed to investigate
the role PON1 activity plays in influencing the
occurrence and extent of migraine incidents, in
order to provide additional information on this
relationship.
The activity of the serum PON1 was noted to
be reduced in a number of pathological conditions
including CAD, hypercholesterolemia, type 2
diabetes, and renal failure (16,17). Previous studies
indicate that PON1 can prevent the accumulation of
lipid peroxide on LDL (10-12). In addition, numerous
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and phenotype as well as the ratio of salt-stimulated
paraoxonase to arylesterase were correlated with
headache duration (Figure 3). These results reveal
that headaches were of shorter duration in patients
with high homozygous activity (PON1192RR = BB
phenotype) (Table 4). To the knowledge of the
authors, there is no study other than the present one
that reports on PON1 activity in MWoA patients.
For this reason the results generated by the present
study could not be compared with any other findings
regarding PON1 activity.

epidemiological studies demonstrated that the rate of
serum PON1 activity decreases in patients suffering
from CAD (10-17). Knowledge about the influence
of the rate of serum PON1 activity on patients
diagnosed with MWoA, however, is limited.
In the present study no differences were observed in
the rate of PON1 activity and phenotype distribution
among the MWoA patients and the controls (Table
3). However, significant differences were noted
between the levels of LOOH and hyperlipidemia
among the 2 groups (Table 2). These results are
consistent with those generated by similar previous
reports (2,5). The molecular mechanisms of migraine
have not yet been completely explained. Therefore, it
is suggested that hyperlipidemia and oxidative stress
may be associated with migraine attacks. Moreover,
it is believed that hyperlipidemia and the consequent
occurrence of LOOH and oxidative stress play a role
in the pathogenesis of migraine (2,5,25,26).

The exact role played by the PON1 phenotype
polymorphism in influencing headache duration in
MWoA patients is uncertain. However, 3 possible
mechanisms have been suggested: 1) The effects
of PON1 on headache duration may be related
to the peroxidase-like activity of PON1 and thus,
PON1 may increase the anti-oxidant capacity that
works against oxidative stress (27). 2) Some studies
conducted on animals indicate that the rate of
PON1 activity can be altered during the acute phase
response, and the serum levels can be decreased. It
was noted, however, that this decrease was transient
since the rate of PON1 activity became equivalent to
the values of the control group within 48 h (28). In
the light of the findings of this study PON1 activity
decreases oxidative stress; consequently, headache
duration also lessens. 3) An incident of migraine
is best understood as a neurovascular disturbance
which leads to vasodilatation and the release of proalgesic substances within the dura mater which in
turn sensitizes peripheral and central neurons (1).
Previous studies have shown that the activity of serum

No differences were noted in the rate of PON1
activity and the levels of HDL-C when comparing
the patient group with the control group (Table 1).
In contrast, the rate of PON1 activity was found to
be inversely correlated with the levels of LOOH in
the MWoA patients evaluated in the present study.
Thus, there may be link between atherosclerosis and
MWoA due to increased levels of LOOH which are
produced by the oxidation of lipids (25,26).
Further, the rate of PON1 activity and phenotype
were not correlated with migraine duration, headache
frequency, mean value of VAS, or mean value of
MIDAS in the present study; the rate of PON1 activity

Table 4. The parameters of PON1 phenotype and headache duration in patients diagnosed with MWoA.*

Phenotype

Headache duration (h)
0-12 (n)

12-24 (n)

24-36 (n)

36-48 (n)

BB (RR)

5

2

1

AB(QR)

9

16

3

AA (QQ)

4

23

4

9

Total (n)

18

41

8

9

*The data are presented as n, used x2 test for all groups, and P < 0.001 was found
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PON1 is closely associated with the modulation of
endothelial functions (13). Thus, PON1 activity can
modulate the neurovascular disturbances which
increase headache duration in incidents of migraine.
In conclusion, the results generated by this study
indicate that an increase in the rate of PON1 activity

may play a significant role in headache duration
during incidents of migraine by increasing degree
of susceptibility to LOOH. In addition, the present
study demonstrated that the distribution of PON1
phenotype may significantly contribute to decreased
headache duration during incidents of migraine.
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